《高盛認股證牛熊證》藥明獲列行業首選 資金積極部署好倉 留意貼價購28300、高槓杆購26102
正股表現:藥明生物(2269)昨日失守110元水平收市,跌約4.9%,並曾低見99.85元,創半年低位。今早繼續下跌,早上低開約3.4%後跌幅收窄。現報103.1元,跌約1.6%。
有券商指藥明生物管理層將今年收入及經常性溢利的增長指引由65%提升至75%,並將明年增長指引從40%提升至45%。該行料可刺激股價向好,並將藥明生物列爲行業首選,給予目標價175元及「增持」投資評級。
資金流向:觀察個股輪證資金流向,可見昨日資金趁低積極部署好倉,錄得約1,020萬元資金流入,爲昨日最多資金流入的相關資產。認購證於本週三及本週四共錄得約710萬元資金流入。牛證於昨日亦獲資金繼續流入,有約480萬元,並較集中在90至92元,及94至96元收回區域的產品。
產品選擇:投資者如看好,認購證方面的貼價選擇可留意屬行使價100至125元間、2個月期以上產品中,槓桿最高的藥明購28300。高槓杆選擇可留意年期約3個月的低街貨藥明購26102。
藥明購28300,行使價125元,2022年05月23日到期,實際槓桿4.2倍,貼價、行使價100至125元間、2個月期以上產品中,槓桿最高
藥明購26102,行使價138元,2022年01月21日到期,實際槓桿7.5倍,低街貨、高槓杆
牛證方面,投資者可留意藥明牛59439,與現價有約18元收回距離。
藥明牛59439,收回價85元,行使價83.5元,換股比率100,槓桿比率5.2倍,相近收回價牛證中槓桿最高
注: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.